(Q45849753)

16 December 2017

title

A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults (English)

1 reference

16 December 2017

1 reference

1 reference

1 reference

3

1 reference

16 December 2017

author name string

A Avihingsanon

1

1 reference

16 December 2017

J van der Lugt

2

1 reference

16 December 2017

M Gorowara

4

1 reference

16 December 2017

S Chanmano

5

1 reference

16 December 2017

P Ohata

6

1 reference

16 December 2017

J Lange

7

1 reference

16 December 2017

D A Cooper

8

1 reference

16 December 2017

P Phanuphak

9

1 reference

16 December 2017

D M Burger

10

1 reference

16 December 2017

K Ruxrungtham

11

1 reference

16 December 2017

language of work or name

English

0 references

publication date

31 December 2008

1 reference

16 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

16 December 2017

volume

85

1 reference

16 December 2017

issue

4

1 reference

16 December 2017

page(s)

402-408

1 reference

16 December 2017

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Atazanavir: a review of its use in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Atazanavir: new option for treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

1 reference

7 January 2021

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Individual genomes instead of race for personalized medicine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

"Getting the dose right": facts, a blueprint, and encouragements

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Aging biology and geriatric clinical pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.244

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.244

1 reference

16 December 2017

Dimensions Publication ID

1048733381

0 references

1 reference

16 December 2017